All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can ...
In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback